These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

17 related articles for article (PubMed ID: 18637063)

  • 1. The optimal threshold: Baseline serum hepatitis B virus DNA and alanine transaminase levels can predict the 2-Year on-treatment virological response to lamivudine.
    Yan J; Xie W; Wang Q; Li Y; Feng X; Cheng J
    Hepat Mon; 2011 May; 11(5):358-63. PubMed ID: 22087161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.
    Chien RN; Liaw YF; Atkins M
    Hepatology; 1999 Sep; 30(3):770-4. PubMed ID: 10462384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pretreatment ALT level and histologic activity as predictors of HBeAg loss in lamivudine treatment for chronic hepatitis B].
    Kweon YO; Kang KH
    Korean J Hepatol; 2004 Mar; 10(1):31-41. PubMed ID: 15096715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
    Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
    Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment alanine transaminase level may not be the most important predictor of HBeAg loss in the older patient.
    Lee JI; Park HJ; Lee JW; Kim YS; Jeong S; Lee DH; Kim HG; Shin YW; Kwon KS
    Liver Int; 2009 Feb; 29(2):231-6. PubMed ID: 18637063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trial results and treatment resistance with lamivudine in hepatitis B.
    Wright TL
    Semin Liver Dis; 2004; 24 Suppl 1():31-6. PubMed ID: 15192799
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.